On Thursday, RBC Capital Markets adjusted its outlook on Alnylam Pharmaceuticals (NASDAQ:ALNY), increasing the stock’s price target to $265 from the previous $250 while maintaining an Outperform rating. This change reflects the firm’s heightened confidence in Alnylam’s product, Amvuttra, and its potential as a leading treatment for transthyretin-mediated cardiomyopathy (TTR-CM).
The optimism from RBC Capital stems from recent discussions with Alnylam’s top executives, who are confident in Amvuttra’s ability to become the preferred first-line therapy for TTR-CM. Their confidence is based on impressive clinical results, including a 36% mortality reduction and positive outcomes across all primary and secondary endpoints in recent trials. Additionally, Amvuttra has shown an additive effect when used in combination with tafamidis (tafa), another medication for TTR-CM.
Alnylam plans to file for regulatory approval within the next three to four months, with the possibility of obtaining approval in early 2025. The use of a Priority Review Voucher (PRV) and the likelihood of forgoing an Advisory Committee (AdCom) could expedite the process. The company’s executives also hinted at a strong commercial strategy, given the current $4.5 billion market for tafamidis and the potential for Amvuttra to become the new standard treatment upon approval.
In addition to the positive clinical data, Alnylam’s strategy for life-cycle management of Amvuttra was highlighted by RBC Capital. The company is considering an annual dosing regimen for its next-generation product, which could begin pivotal trials by the end of the year. This approach could also help Alnylam avoid a 15-30% royalty payment to Sanofi (NASDAQ:).
RBC Capital’s increased price target is also influenced by Alnylam’s clear path to profitability, with a goal to break even by next year. The firm sees Alnylam’s platform as de-risked with potential across various indications and views the company as an attractive candidate for mergers and acquisitions.
In other recent news, Alnylam Pharmaceuticals has demonstrated significant progress through successful outcomes from its HELIOS-B Phase 3 trial for vutrisiran, a therapeutic designed for patients with transthyretin-mediated amyloidosis cardiomyopathy (ATTR-CM). The trial met its primary endpoint, showing significant improvements in cardiovascular outcomes, including survival rates. Following the positive trial results, Alnylam plans to submit a supplemental New Drug Application to the FDA for vutrisiran in ATTR-CM by the end of 2024.
On the financial front, Alnylam’s Q1 2024 revenues reached $365 million, marking a 32% increase from the same period the previous year, primarily driven by its Transthyretin (TTR) franchise. The company is targeting net product revenues between $1.4 billion and $1.5 billion for 2024.
Investment firms H.C. Wainwright, Morgan Stanley, BMO Capital, and Stifel have maintained their positive ratings for Alnylam, reflecting their confidence in the company’s growth trajectory and the commercial prospects of vutrisiran. However, TD Cowen maintained a Buy rating on shares of BridgeBio Pharma (NASDAQ:), suggesting that Alnylam’s results did not meet the high expectations set by BridgeBio’s ATTRibute-CM trial results.
InvestingPro Insights
Recent data from InvestingPro provides a comprehensive look at Alnylam Pharmaceuticals’ financial health and market performance. With a robust market capitalization of $31.01 billion, Alnylam shows significant promise in the biotech industry. Despite the lack of profitability in the last twelve months, as indicated by a negative P/E ratio of -92.38, the company’s revenue has grown impressively by 75.2% over the same period. This substantial revenue growth is a testament to Alnylam’s strong commercial potential, particularly as it gears up for the approval of Amvuttra.
InvestingPro Tips suggest that Alnylam’s stock is currently in overbought territory, which may be reflective of the recent positive outlook and high expectations from investors. Additionally, the stock has experienced a significant return over the last week, month, and three months, with a 55.76%, 65.92%, and 58.8% price total return respectively, aligning with the confidence expressed by RBC Capital Markets. Moreover, Alnylam’s liquid assets surpass its short-term obligations, indicating a healthy liquidity position that could support its upcoming commercial strategies.
For readers seeking a deeper analysis, InvestingPro offers more tips on Alnylam, which can be accessed through the platform. Use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription, and discover the full range of insights available, including the numerous additional tips listed in InvestingPro that can help inform investment decisions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.